PIK3CA and neoplasm: In the HBCx-17 model (WT for PIK3CA), only the combination of BYL719 + fulvestrant inhibited tumor growth with a TGI of 64% (P = 0.03, Mann-Whitney t test), although no tumor regression was observed (Fig.6a).